Podcast: Biosimilar Development - - BioPharm International

ADVERTISEMENT

Podcast: Biosimilar Development


blog comments powered by Disqus


Anjan Selz, cofounder and CEO of Finox Biotech, takes us on the exciting journey from cell bank to Phase III, something that was achieved in just four years for his company’s biosimilar product, Afolia. In this first of three podcasts, Selz notes that Finox Biotech decided very early on that it wanted to move away from the “me too” approach to biosimilars and focus on product differentiation. Selz goes into detail about biosimilar candidate selection using Afolia (a follicle stimulating hormone), as an example, and describes the importance of having a good understanding of the patent landscape. Selz describes Finox’s outsourcing strategies in terms of partner selection—notably, all are based in Western Europe, and also offers insight into creating meaningful relationships in which success is a shared goal. Posted Dec. 2011.

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here